HPV vaccines
AssigneeJanssen Vaccines & Prevention B.V.
InventorsMarija Vujadinovic, Taco Gilles Uil, Koen Oosterhuis, Jort Vellinga, Jerôme Hubertina Henricus Victor Custers
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel vaccines against Human papillomavirus (HPV) infections, based on recombinant capsid-display adenovirus vectors. Described are capsid modified replication deficient adenovirus particles encoding and displaying multiple HPV L2 antigenic fragments, via a minor capsid protein IX, and their use for eliciting an immune response in order to provide protection against infections from multiple HPV types.
Claims25
A recombinant adenoviral vector encoding a polypeptide comprising a capsid protein IX fused to an antigen, wherein said antigen comprises the amino acid sequence of SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 6, or SEQ ID NO:
- 7.
A recombinant adenoviral vector encoding a polypeptide comprising a capsid protein IX fused to an antigen, wherein said antigen comprises 4 consecutive amino acid motifs of about 20 to about 40 amino acids, wherein the first motif comprises the amino acid residues 17-36 of a HPV L2 protein of the HPV type 31, the second motif comprises the amino acid residues 69-81 of a HPV L2 protein of the HPV type 45, the third motif comprises the amino acid residues 108-121 of a HPV L2 protein of the HPV type 18, and the fourth motif comprises the amino acid residues 108-121 of a HPV L2 protein of the HPV type 16.
Dependencies are inferred from the claim text.